Multiple Sleep Latency Test (MSLT) and Maintenance of Wakefulness Test (MWT)
Customize your policy alerts
Sign up for Aetna Policy 0330 alerts
Get alerted when Policy 0330 changes without checking for updates manually.
Monitor payer policy activity
Defines Aetna's medical necessity, investigational status, and coding guidance for facility-based MSLT and MWT for evaluation of narcolepsy and idiopathic hypersomnia; applies to providers submitting claims to Aetna.
No material clinical or coverage changes in this revision.
Coverage Criteria for MSLT and MWT
inv-01: Medical Necessity Indications
Covered when ANY of the following are met:
Aetna considers MSLT and MWT medically necessary for evaluation of narcolepsy per policy and AASM guidance.
Aetna considers MSLT and MWT medically necessary for this indication; consistent with AASM guidance.
inv-02: Repeat Testing Criteria
Repeat MSLT/MWT are NOT medically necessary UNLESS ALL of the following exception conditions apply (repeat permitted if any one exception applies):
Repeat testing allowed when initial study cannot be interpreted.
Repeat testing allowed when study conditions were inadequate.
Repeat testing allowed to obtain polygraphic confirmation for suspected narcolepsy.
inv-03: Experimental and Investigational
MSLT and MWT are considered experimental and investigational (not covered) for the following and other non-listed indications:
Home MSLT considered experimental per policy.
Single nap studies considered experimental per policy.
Listed among indications lacking established effectiveness.
Listed among indications lacking established effectiveness.
Listed among indications lacking established effectiveness.
Listed among indications lacking established effectiveness.
Listed among indications lacking established effectiveness.
Listed among indications lacking established effectiveness.
Listed among indications lacking established effectiveness.
Listed among indications lacking established effectiveness.
Listed among indications lacking established effectiveness.
Listed among indications lacking established effectiveness.
List is not all-inclusive; other non-listed uses are considered investigational.
inv-04: Evidence summaries and diagnostic thresholds
Summaries of clinical evidence relevant to diagnostic interpretation and test utility:
Use pediatric-specific thresholds and adjunctive data (PSG, CSF hypocretin, cataplexy) when available.
Home MSLT mean sleep latency comparable but SOREMP rates differed; clinical utility not established.
Interpretation should consider heterogeneity and limited discriminative value in psychiatric populations.
MSLT and MWT are not routinely indicated for the initial evaluation of obstructive sleep apnea or for assessment of change following CPAP therapy. The policy also lists these tests as not routinely indicated for evaluation of sleepiness in medical and neurologic disorders (other than narcolepsy), insomnia, circadian rhythm disorders, and several other conditions reflected in the ICD-10 examples (for example, dementias, Parkinson's disease, primary insomnia, and obstructive sleep apnea) that are identified as not covered for the CPB indications.
Home-based MSLT and single-nap studies are specifically considered experimental/investigational (not covered) because they have not been proven equivalent to formal, facility-based MSLT and a full MSLT or MWT is required for accurate diagnosis of narcolepsy.
An UpToDate review on adult ADHD does not list MSLT as a management tool. The policy cites that UpToDate (Bukstein, 2016) does not recommend MSLT for routine use in the assessment or management of adult ADHD, and supporting primary studies reported no consistent difference in mean MSLT sleep latency between adults with ADHD and controls.
Repeat MSLT and MWT are considered not medically necessary except when one or more of the following conditions applies: the initial test was invalid or uninterpretable; the initial test was affected by extraneous circumstances or required study conditions were not present; or the patient is suspected to have narcolepsy but earlier MSLT/MWT did not provide polygraphic confirmation.
The policy notes that MSLT and MWT are facility-based studies performed under defined protocols (MSLT typically after a nocturnal PSG with at least six hours of sleep using five 20-minute nap trials separated by two-hour intervals; MWT typically uses four 40-minute trials). Single-nap studies and home MSLT are not acceptable substitutes for repeat in-lab testing and are considered experimental/investigational or not medically necessary when used to replace a full, facility-based study.
Evidence assessing MSLT performance in psychiatric hypersomnolence is limited and heterogeneous. Early work (Nofzinger et al., 1991) found that patients with hypersomnia related to mood disorders did not show the REM-related daytime nap abnormalities typical of narcolepsy, and more recent systematic review data (Plante, 2016) show high heterogeneity with a pooled sleep propensity similar to normative values.
Approximately 25% of patients with psychiatric hypersomnolence may demonstrate a mean sleep latency below the commonly used pathologic cut-point (8 minutes), underscoring that MSLT findings in psychiatric populations can overlap with other CNS causes of sleepiness and may not reliably distinguish psychiatric hypersomnolence from other disorders.
Coding and Diagnostic Thresholds
| 95805 | Multiple sleep latency or maintenance of wakefulness testing, recording, analysis and interpretation of physiological measurements of sleep during multiple trials to assess sleepiness. |
| 95782 | Polysomnography; younger than 6 years, sleep staging with 4 or more additional parameters of sleep, attended by a technologist. |
| 95806 | Sleep study. |
| 95807 | Sleep study. |
| 95808 | Polysomnography; sleep staging, attended by a technologist. |
| 95809 | Polysomnography; sleep staging, attended by a technologist. |
| 95810 | Polysomnography; sleep staging, attended by a technologist. |
| 95811 | Polysomnography; sleep staging, attended by a technologist. |
| G47.10 - G47.19 | Hypersomnia |
| G47.411 - G47.429 | Narcolepsy and cataplexy |
| G47.53 | Recurrent isolated sleep paralysis |
| R44.0 - R44.3 | Hallucinations |
| R53.81 - R53.83 | Other malaise and fatigue [excessive or extreme sleepiness] |
| F01.50 - F03.91 | Dementias |
| G20 | Parkinson's disease |
| G47.33 | Obstructive sleep apnea (adult) (pediatric) |
| G47.00 | Insomnia, unspecified |
Provider Actions, Billing, and Denial Risk
CPT 95805 covered when selection criteria met
CPT 95805 (Multiple sleep latency or maintenance of wakefulness testing) is covered when the policy's selection criteria for MSLT/MWT are met.
- Covered only for: 1) evaluation to confirm narcolepsy; or 2) evaluation to help differentiate idiopathic hypersomnia from narcolepsy.
No explicit prior authorization procedures stated
The document does not specify any explicit prior authorization requirements or list payer-level authorization triggers or affected billing codes beyond stating coverage conditions for CPT 95805.
Restrictions on repeat MSLT/MWT
Repeat MSLT or MWT is not routinely covered; repeat testing is allowed only when the initial test was invalid or uninterpretable, was affected by extraneous circumstances or inappropriate study conditions, or earlier testing did not provide polygraphic confirmation for suspected narcolepsy.
- Repeat testing permitted if: initial test invalid/uninterpretable; or initial test affected by extraneous circumstances or inappropriate study conditions; or earlier MSLT/MWT lacked polygraphic confirmation.
Optimize anti‑parkinsonian therapy before disorder‑specific testing
For Parkinson's disease–related sleep complaints, management typically begins with optimization of anti‑parkinsonian (dopaminergic) therapy before initiating disorder‑specific testing such as MSLT/MWT.
- No step‑therapy rules for MSLT/MWT are specified, but PD sleep disorder care should start with medication optimization and screening questionnaires, then referral/testing as needed.
Required facility‑based study conditions and nap trial protocol
MSLT and MWT should be performed as facility‑based studies after a nocturnal polysomnography (PSG) with adequate sleep; routine MSLT uses five 20‑minute nap trials separated by two‑hour intervals, while MWT typically uses four 40‑minute trials with a similar protocol.
- Nightly PSG should show at least six hours of sleep prior to daytime testing.
- MSLT: five 20‑minute nap trials separated by two hours.
- MWT: four 40‑minute trials; protocol similar to MSLT but assesses ability to stay awake.
Required supporting diagnostic data for interpreting MSLT
Provide diagnostic elements required to interpret MSLT: report mean sleep latency and number of SOREMPs; when available, include adjunctive nocturnal PSG data and, in pediatric evaluation, CSF hypocretin‑1 and cataplexy status as relevant.
- Include mean sleep latency and count of SOREMPs from MSLT.
- Attach prior nocturnal PSG results (e.g., sleep duration and staging) used to exclude other causes of sleepiness.
- In pediatric cases, include CSF hypocretin‑1 results and cataplexy status when available to support NT1 diagnosis.
Denial risk for unsupported repeat testing
Denials are likely if repeat MSLT or MWT are requested without meeting exception conditions; repeat testing is considered not medically necessary unless the initial study was invalid/uninterpretable, affected by extraneous circumstances or inadequate study conditions, or lacked polygraphic confirmation for suspected narcolepsy.
- Document the specific exception that justifies repeat testing (invalid result, extraneous circumstances/inadequate conditions, or need for polygraphic confirmation).
No explicit authorization/denial procedures specified in policy
No explicit payer procedural authorization triggers or denial processes are described in the policy text; the policy cites practice parameters and references as the evidentiary basis for coverage decisions rather than specifying separate authorization procedures.
- Use cited practice parameters and references (AASM guidance, AIM, and listed studies) to support medical necessity determinations.
- No separate administrative prior‑authorization workflow is defined in these chunks.
Background and Scope
The Multiple Sleep Latency Test (MSLT) is a facility-based, objective measure of daytime sleepiness used primarily to confirm narcolepsy and to help differentiate idiopathic hypersomnia from narcolepsy. Routine MSLT protocol involves multiple daytime nap opportunities (typically five 20-minute trials separated by two-hour intervals) and is usually performed the day after a nocturnal polysomnogram (PSG) with adequate sleep.
The Maintenance of Wakefulness Test (MWT) is a related facility-based measure of the ability to stay awake, generally consisting of four 40-minute trials using a protocol similar to the MSLT but focused on wakefulness and often used to assess treatment efficacy or safety concerns about wakefulness.
Interpretation of MSLT requires adjunctive information when available (nocturnal PSG, clinical history including cataplexy, and in select pediatric cases CSF hypocretin-1) and relies on objective metrics such as mean sleep latency and the count of SOREMPs to support diagnostic conclusions.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.